These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 5309476)

  • 1. Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67.
    Eickhoff TC; Meiklejohn G
    Bull World Health Organ; 1969; 41(3):562-3. PubMed ID: 5309476
    [No Abstract]   [Full Text] [Related]  

  • 2. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.
    Hilleman MR
    Bull World Health Organ; 1969; 41(3):623-8. PubMed ID: 4985377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience in Yugoslavia with live influenza vaccine prepared from an attenuated A2-Hong Kong-68 strain.
    Ikić D
    Bull World Health Organ; 1969; 41(3):608-9. PubMed ID: 5309485
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
    Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].
    Sarateanu DE; Ehrengut W
    Fortschr Med; 1981 Sep; 99(34):1348-52. PubMed ID: 7026399
    [No Abstract]   [Full Text] [Related]  

  • 9. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004.
    Herrera GA; Iwane MK; Cortese M; Brown C; Gershman K; Shupe A; Averhoff F; Chaves SS; Gargiullo P; Bridges CB
    Vaccine; 2007 Jan; 25(1):154-60. PubMed ID: 17064823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against Hong Kong influenza in Japan.
    Fukumi H
    Bull World Health Organ; 1969; 41(3):555. PubMed ID: 5309473
    [No Abstract]   [Full Text] [Related]  

  • 11. A field trial of Hong Kong-strain influenza vaccine in Seattle schoolchildren.
    Foy HM; Cooney M; McMahan R; Grayston JT
    Bull World Health Organ; 1969; 41(3):564-6. PubMed ID: 5309477
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.
    Li S; Perdue ML; Patzer E
    Dev Biol (Basel); 2002; 110():135-41. PubMed ID: 12477316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccination against influenza in the elderly. Experience with adjuvant vaccines].
    Baldo V; Menegon T; Buoro S; Scalici C; Vesco A; Perale S; Boato W; Carletti M; Bonello C; Dalla Costa D; Trivello R
    Ann Ig; 1999; 11(5):369-74. PubMed ID: 10596424
    [No Abstract]   [Full Text] [Related]  

  • 16. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A universal epitope-based influenza vaccine and its efficacy against H5N1.
    Adar Y; Singer Y; Levi R; Tzehoval E; Perk S; Banet-Noach C; Nagar S; Arnon R; Ben-Yedidia T
    Vaccine; 2009 Mar; 27(15):2099-107. PubMed ID: 19356612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccine with squalene adjuvant: new preparation. No better than available products.
    Prescrire Int; 2004 Dec; 13(74):206-8. PubMed ID: 15599987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.